CML Treatment: Scenarios that Necessitate Switching Therapy
Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.
EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment
EP: 2.Navigating CML: Tools to Empower Patients and Caregivers
EP: 3.Empowering CML Caregivers: Strategies and Support Systems
EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes
EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
Now Viewing
EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy
EP: 8.Ensuring Informed CML Care from Diagnosis Onward
EP: 9.Advancing CML Management Towards an Ideal Patient Journey
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- In which scenarios do you consider switching CML therapies, and how do you approach that conversation with patients? How does the patient experience change when switching therapies?
Recent Videos
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Related Content
